340 related articles for article (PubMed ID: 7481863)
21. Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis.
Neijt JP; Engelholm SA; Witteveen PO; Tuxen MK; Sørensen PG; Hansen M; Hirsch F; Sessa C; de Swart C; van Houwelingen HC; Lund B; Hansen SW
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-36-S15-39. PubMed ID: 9346220
[TBL] [Abstract][Full Text] [Related]
22. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
23. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Aravantinos G; Fountzilas G; Bamias A; Grimani I; Rizos S; Kalofonos HP; Skarlos DV; Economopoulos T; Kosmidis PA; Stathopoulos GP; Briasoulis E; Pectasides D; Samantas E; Timotheadou E; Papadimitriou C; Papanikolaou A; Onyenadum A; Papakostas P; Bafaloukos D; Dimopoulos MA;
Eur J Cancer; 2008 Oct; 44(15):2169-77. PubMed ID: 18691879
[TBL] [Abstract][Full Text] [Related]
24. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
25. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ;
J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432
[TBL] [Abstract][Full Text] [Related]
26. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
[TBL] [Abstract][Full Text] [Related]
27. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy of advanced ovarian cancer.
McGuire WP; Ozols RF
Semin Oncol; 1998 Jun; 25(3):340-8. PubMed ID: 9633846
[TBL] [Abstract][Full Text] [Related]
29. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
30. Systemic therapy for ovarian cancer: current status and new treatments.
Ozols RF
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
[TBL] [Abstract][Full Text] [Related]
31. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
32. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
[TBL] [Abstract][Full Text] [Related]
33. Future directions in the chemotherapy of ovarian cancer.
Ozols RF
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
International Collaborative Ovarian Neoplasm Group
Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
[TBL] [Abstract][Full Text] [Related]
35. A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505).
Saito I; Kitagawa R; Fukuda H; Shibata T; Katsumata N; Konishi I; Yoshikawa H; Kamura T
Jpn J Clin Oncol; 2010 Jan; 40(1):90-3. PubMed ID: 19825815
[TBL] [Abstract][Full Text] [Related]
36. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Ozols RF; Bundy BN; Greer BE; Fowler JM; Clarke-Pearson D; Burger RA; Mannel RS; DeGeest K; Hartenbach EM; Baergen R;
J Clin Oncol; 2003 Sep; 21(17):3194-200. PubMed ID: 12860964
[TBL] [Abstract][Full Text] [Related]
37. A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer.
Fujiwara K; Aotani E; Hamano T; Nagao S; Yoshikawa H; Sugiyama T; Kigawa J; Aoki D; Katsumata N; Takeuchi M; Suzuki M
Jpn J Clin Oncol; 2011 Feb; 41(2):278-82. PubMed ID: 20937602
[TBL] [Abstract][Full Text] [Related]
38. [Controversies regarding intraperitoneal chemotherapy for advanced ovarian cancer].
Miron L; Onofriescu M; Marinca M
Rev Med Chir Soc Med Nat Iasi; 2008; 112(3):583-9. PubMed ID: 20201236
[TBL] [Abstract][Full Text] [Related]
39. Current status of taxane and platinum-based chemotherapy in ovarian cancer.
McGuire WP
J Clin Oncol; 2003 May; 21(10 Suppl):133s-135s. PubMed ID: 12743128
[TBL] [Abstract][Full Text] [Related]
40. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]